First Trust Biotechnology Fund (FBT)
XMIL 
Summary
FBT Chart
FBT: This 30-Stock Biotech ETF Isn't Worth The Risk Today
FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional returns compared to the broader Health Care sector, despite its high 0.56% expense ratio. A closer look at performance reveals that FBT is subject to periods of significant gains and losses, though it has struggled over the last five and ten-year periods.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Designed to provide broad exposure to the Health Care ETFs category of the market, the First Trust NYSE Arca Biotechnology ETF (FBT) is a smart beta exchange traded fund launched on 06/19/2006.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange traded fund launched on 06/19/2006.
First Trust Biotechnology Fund Dividends
| FBT 30 Dec 2021 Paid | Other | $2.21 Per Share |
| FBT 23 Sep 2015 Paid | Quarterly | $0.02 Per Share |
| FBT 24 Jun 2015 Paid | Quarterly | $0.06 Per Share |
| FBT 25 Mar 2015 Paid | Quarterly | $0.05 Per Share |
| FBT 23 Dec 2014 Paid | Quarterly | $0.05 Per Share |
First Trust Biotechnology Fund Earnings
| FBT 30 Dec 2021 Paid | Other | $2.21 Per Share |
| FBT 23 Sep 2015 Paid | Quarterly | $0.02 Per Share |
| FBT 24 Jun 2015 Paid | Quarterly | $0.06 Per Share |
| FBT 25 Mar 2015 Paid | Quarterly | $0.05 Per Share |
| FBT 23 Dec 2014 Paid | Quarterly | $0.05 Per Share |
First Trust Biotechnology Fund (FBT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has First Trust Biotechnology Fund ever had a stock split?
First Trust Biotechnology Fund Profile
| XMIL Exchange | US Country |
Overview
This financial entity operates as an investment fund focusing predominantly on the biotechnology sector. It is structured to track the performance of 30 leading biotechnology companies, employing a strategic approach by allocating at least 90% of its net assets (this includes any borrowed investments) directly into the securities that form the basis of its targeted index. The index itself is constructed on an equal-dollar weighted basis, ensuring that each company within the index has an equal influence on the fund's overall performance. This method is designed to provide investors with a diversified exposure to the biotechnology industry, capturing the growth and innovation within this sector.
Products and Services
- Biotechnology Equity Investments
The primary offering of this fund revolves around equity investments in biotechnology companies. By focusing on 30 leading firms within the sector, the fund aims to tap into the growth potential of biotechnological advancements and innovations. This approach allows investors to gain exposure to a wide array of companies developing novel therapies, medical devices, and diagnostic tools, among other contributions to the healthcare sector.
Contact Information
